Noboru Yamamoto

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto, Terufumi Kato, Makoto Nishio et al. · The Lancet Oncology · 2014 · 745 citations

First-line Therapy, Oncology, Pathology +8

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Toshimi Takano, Yuichiro Ohe, Hiromi Sakamoto et al. · Journal of Clinical Oncology · 2005 · 706 citations · Full text

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo et al. · Cancer Science · 2019 · 351 citations · Full text

Actionable Gene Aberrations, Cancer Pathology, Hospital‐based Study +22

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

Yi‐Long Wu, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2018 · 321 citations · Full text

Pathology, Phase Ii Study, Oncology +16

Development of a new pH-swing CO2 mineralization process with a recyclable reaction solution

Satoshi Kodama, Takuma Nishimoto, Noboru Yamamoto et al. · Energy · 2008 · 306 citations

Chemical Engineering, Sustainable Chemical Production, Engineering +7